TLR2 and metabolic disease: In addition to attenuating these inflammatory diseases, Sj-Cys attenuated metabolic diseases and atherosclerosis like atherosclerotic renal damage through promoting Treg and M2 macrophage polarization, mediated by inhibiting the Toll-like receptor 2 (TLR2)/MYD88 signaling pathway[27].